1-20 of 23021
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia

Open Access
Clinical Trials & Observations
Mathilde Chanut, Aurélie Cabannes-Hamy, Marie Balsat, Nassim Sahki, Emmanuel Raffoux, Yosr Hicheri, Bruno Lioure, Lucie Laemmel, Thibaut Leguay, Victoria Cacheux, Maria Pilar Gallego-Hernanz, Andrea Pieragostini, Gabrielle Roth-Guepin, Ludovic Gabellier, Nathalie Denizon, Lise Willems, Quentin Cabrera, Sylvain Chantepie, Valérie Coiteux, Claudie Capdupuy, Martin Carré, Antoine Machet, Juliette Lambert, Sandrine Roux, Franck-Emmanuel Nicolini, Nicolas Boissel, Emmanuelle Clappier, Rathana Kim, Philippe Rousselot
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4580–4584.
https://doi.org/10.1182/bloodadvances.2025016665
Published: 2025
Includes: Supplemental data
Images
Outcomes of patients treated with ASC. (A) OS of patients with R/R Ph+ ALL/LBC-ALL treated with ASC. (B) OS of patients with R/R Ph+ ALL/LBC-ALL treated with ASC in combination (blue) or as monotherapy (red). (C) EFS of patients with R/R Ph+ ALL/LBC-ALL treated with ASC. (D) EFS of patients treated with ASC in combination (blue) or as monotherapy (red).

Outcomes of patients treated with ASC. (A) OS of patients with R/R Ph + A...

Open Access
in Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia > Blood Advances
Published: 2025
Figure 1. Outcomes of patients treated with ASC. (A) OS of patients with R/R Ph + ALL/LBC-ALL treated with ASC. (B) OS of patients with R/R Ph + ALL/LBC-ALL treated with ASC in combination (blue) or as monotherapy (red). (C) EFS of patients with R/R Ph + ALL/LBC-ALL treated with ASC. (D) EFS ... More about this image found in Outcomes of patients treated with ASC. (A) OS of patients with R/R Ph + A...
Journal Articles

National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease

Open Access
Stephanie Howe Guarino, Akshat Jain, Mohan Madisetti, Kenneth Rivlin, Payal C. Desai, Julie Kanter, Sophie Lanzkron, Deepa Manwani
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4585–4591.
https://doi.org/10.1182/bloodadvances.2025015909
Published: 2025
Includes: Supplemental data
Journal Articles

Elucidating the dynamics of integrin αIIbβ3 from native platelet membranes by cryo-EM with build-and-retrieve method

Open Access
Xu Han, Zhemin Zhang, Chih-Chia Su, Meinan Lyu, Masaru Miyagi, Edward Yu, Marvin T. Nieman
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4592–4606.
https://doi.org/10.1182/bloodadvances.2025016209
Published: 2025
Includes: Multimedia, Supplemental data
Journal Articles

Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia

Open Access
Clinical Trials & Observations
Andrew R. Branagan, Clifton Mo, Matthew Lei, Joshua N. Gustine, Andrew J. Yee, Elizabeth O’Donnell, Jorge J. Castillo, Omar Nadeem, Catherine Flynn, Zachary Bernstein, Rie Nakamoto-Matsubara, Kirsten Meid, Rakesh Verma, Zachary R. Hunter, Maria L. Guerrera, Galit Alter, Jill Burke, Cynthia Harrington, Emerentia Agyemang, Marilyn Gammon, Kathleen Lively, Lisette Packer, Nora Horick, Jacob Laubach, Constantine S. Mitsiades, Nikhil Munshi, Kenneth C. Anderson, Steven P. Treon, Paul G. Richardson, Noopur S. Raje, Shayna R. Sarosiek
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4568–4579.
https://doi.org/10.1182/bloodadvances.2025016513
Published: 2025
Journal Articles

Serum TARC: a biomarker for early detection or exclusion of relapse in classic Hodgkin lymphoma

Open Access
Sophie A. Teesink, Lydia Visser, Marcel Nijland, Kylie Keijzer, Anne G. H. Niezink, Bart-Jan Kroesen, Anke van den Berg, Arjan Diepstra, Wouter J. Plattel
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4618–4621.
https://doi.org/10.1182/bloodadvances.2025015837
Published: 2025
Includes: Supplemental data
Journal Articles

Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma

Open Access
Clinical Trials & Observations
Xian G. Zhang, Lin Wang, Junfang Yang, Xiaona N. Hu, Hui Wang, Lina N. Zhang, Xiaoge Zhou, Ying Liu, Qinglong Wang, Peihua H. Lu
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4543–4552.
https://doi.org/10.1182/bloodadvances.2025016322
Published: 2025
Includes: Supplemental data
Journal Articles

PROM1 /CD133 marks a proliferative stem cell-like population of blasts in KMT2A rearranged infant ALL

Open Access
Joe Wilson Cross, Lucy Field, Alastair Smith, Emily Neil, Lucy Hamer, Thomas Jackson, Natalina Elliott, Siobhan Rice, Nicholas Crump, Joe Harman, Rebecca E. Ling, Qingqing Wu, Nouhad El Ouazzani, Rebecca Thomas, Sarah Inglott, Jack Bartram, Owen Smith, Jonathan Bond, Irene Roberts, Thomas A. Milne, Anindita Roy
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4607–4613.
https://doi.org/10.1182/bloodadvances.2024015185
Published: 2025
Includes: Supplemental data
Journal Articles

Deleting ACC1 in platelets alters phospholipidome and reduces platelet activation and thrombosis in mice

Open Access
Marie Octave, Laurence Pirotton, Emma de Cartier d’Yves, Alice Marino, Jérôme Ambroise, Martin Giera, Bruno Guigas, Audrey Ginion, Valentine Robaux, Marijke Kuijpers, Constance Baaten, Johan W. M. Heemskerk, Zoltan Nagy, Yotis Senis, Davide Brusa, Caroline Bouzin, Luc Bertrand, Christophe Beauloye, Sandrine Horman
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4553–4567.
https://doi.org/10.1182/bloodadvances.2025015796
Published: 2025
Includes: Supplemental data
Journal Articles

Bing-Neel syndrome: a case series of 46 patients from the United Kingdom

Open Access
Clinical Trials & Observations
Oliver Tomkins, Jahanzaib Khwaja, Shiwen Koay, Nicole Japzon, Chandrashekar Hoskote, Rajeev Gupta, Robert Baker, Jindriska Lindsay, Charalampia Kyriakou, Michael P. Lunn, Shirley D’Sa
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4614–4617.
https://doi.org/10.1182/bloodadvances.2025016360
Published: 2025
Journal Articles

Sequential BCMA CAR T-cell therapy in refractory multiple myeloma

Open Access
Tim Richardson, Udo Holtick, Jan-Hendrik Frenking, Hishan Tharmaseelan, Hyatt Balke-Want, Ruth Flümann, Elias Karl Mai, Sandra Sauer, Raphael Teipel, Malte von Bonin, Michael Hallek, Christof Scheid, Philipp Gödel
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4624–4630.
https://doi.org/10.1182/bloodadvances.2025016712
Published: 2025
Journal Articles

A standardized metric to define a successful transition from pediatric to adult care in sickle cell disease

Open Access
Clinical Trials & Observations
Galia Pollock, Susanna Curtis
Journal: Blood Advances
Blood Adv (2025) 9 (18): 4622–4623.
https://doi.org/10.1182/bloodadvances.2025017088
Published: 2025
Images
Geographic distribution of the NASCC member centers as of February 2025. Each dot represents 1 member center (adult, pediatric, and/or life span). The figure was made by one of the authors (M.M.), using a public Esri ArcGIS online trial account, and has not been previously published.

Geographic distribution of the NASCC member centers as of February 2025. E...

Open Access
in National Alliance of Sickle Cell Centers consensus standards for transition to adult care in sickle cell disease > Blood Advances
Published: 2025
Figure 1. Geographic distribution of the NASCC member centers as of February 2025. Each dot represents 1 member center (adult, pediatric, and/or life span). The figure was made by one of the authors (M.M.), using a public Esri ArcGIS online trial account, and has not been previously published. More about this image found in Geographic distribution of the NASCC member centers as of February 2025. E...
Images
CONSORT diagram. Ab, antibody.

CONSORT diagram. Ab, antibody.

Open Access
in Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia > Blood Advances
Published: 2025
Figure 1. CONSORT diagram. Ab, antibody. More about this image found in CONSORT diagram. Ab, antibody.
Images
Functional profiling of SARS-CoV-2 WT spike antibody responses. (A-G) Box plots of IgG1, IgG3, IgM, IgA, FcR2A, FcR2B, FcR3A, or FcR3B titers in log10 MFI. Lines represent the minimum, lower quartile, median, upper quartile, and maximum. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are as indicated. (H) Truncated violin plot of phagoscores from ADCP assay. The dashed lines represent quartiles, with a solid black line for median. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are indicated as follows: not significant (ns), P = .1234; ∗P = .0332; ∗∗P = .0021; ∗∗∗P = .0002; ∗∗∗∗P < .0001. (I) Truncated violin plot of phagoscores from the ADNP assay. The dashed lines represent quartiles, with a solid black line denoting the median. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are indicated as follows: ns, P = .1234; ∗P = .0332; ∗∗P = .0021; ∗∗∗P = .0002; ∗∗∗∗P < .0001. (J) Box plot of antibody-dependent complement deposition, shown as the MFI of FITC+ beads. Lines represent the minimum, lower quartile, median, upper quartile, and maximum. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are as indicated. (K-L) Truncated violin plots of antibody-dependent NK-cell activation: percentage of CD107a+ NK cells or percentage of IFN-γ+ NK cells. Dashed lines represent quartiles, with a solid black line denoting the median. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are indicated as follows: ns, P = .1234; ∗P = .0332; ∗∗P = .0021; ∗∗∗P = .0002; ∗∗∗∗P < .0001. FITC, fluorescein isothiocyanate; IFN-γ, interferon gamma; MFI, median fluorescence intensity.

Functional profiling of SARS-CoV-2 WT spike antibody responses. (A-G) Box ...

Open Access
in Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia > Blood Advances
Published: 2025
Figure 2. Functional profiling of SARS-CoV-2 WT spike antibody responses. (A-G) Box plots of IgG1, IgG3, IgM, IgA, FcR2A, FcR2B, FcR3A, or FcR3B titers in log10 MFI. Lines represent the minimum, lower quartile, median, upper quartile, and maximum. Statistical significance between groups was test... More about this image found in Functional profiling of SARS-CoV-2 WT spike antibody responses. (A-G) Box ...
Images
Figure 3.

Untitled image

Open Access
in Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia > Blood Advances
Published: 2025
Figure 3. More about this image found in Untitled image
Images
Functional profiling of SARS-CoV-2 variants of concern spike antibody responses. (A-G) Box plots of B.1.17 S–, B.1.351 S–, and B.1.617 S–specific IgG1, IgG3, IgM, IgA, FcR2A, FcR2B, FcR3A, or FcR3B titers in log10 MFI. Lines represent the minimum, lower quartile, median, upper quartile, and maximum. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are as indicated. (H-J) Truncated violin plots of B.1.17 S–, B.1.351 S–, and P.1 S–directed ADNP. The dashed lines represent quartiles, with a solid black line denoting the median. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are indicated as follows: ns, P = .1234; ∗P = .0332; ∗∗P = .0021; ∗∗∗P = .0002; ∗∗∗∗P < .0001. (K-M) Truncated violin plots of B.1.17 S–, B.1.351 S–, and P.1 S–directed ADCP. The dashed lines represent quartiles, with a solid black line denoting the median. Statistical significance between groups was tested with a nonparametric Kruskal-Wallis multiple comparisons test. P values are indicated as follows: ns, P = .1234; ∗P = .0332; ∗∗P = .0021; ∗∗∗P = .0002; ∗∗∗∗P < .0001.

Functional profiling of SARS-CoV-2 variants of concern spike antibody respo...

Open Access
in Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenström macroglobulinemia > Blood Advances
Published: 2025
Functional profiling of SARS-CoV-2 variants of concern spike antibody responses. (A-G) Box plots of B.1.17 S–, B.1.351 S–, and B.1.617 S–specific IgG1, IgG3, IgM, IgA, FcR2A, FcR2B, FcR3A, or FcR3B titers in log10 MFI. Lines represent the minimum, lower quartile, median, upper quartile, and maximum... More about this image found in Functional profiling of SARS-CoV-2 variants of concern spike antibody respo...
Images
In vitro function verification of S103 BCMA CAR T cells. (A) Schematic representation of S103 CAR structure. (B) CAR transduction efficiency of S103 CAR T cells. (C) Cell viability of S103 CAR T cells at different culture stages, the x-axis represents the culture days, the red line represents CAR T-cell group, and the blue line represents T-cell group. (D) The cytotoxicity of S103 CAR T cells toward NCI-H929-LUC cancer cells, the x-axis represents the effector-to-target cell ratios, the red line represents CAR T-cell group, and the blue line represents T-cell group. (E) Schematic of animal mode protocol, 6 mice per group, half male and half female, every mouse was injected with 1 × 107 MM.1s-Luc cells. After 8 days, CAR T-cell group was injected with 0.5E7 per mouse CAR+ T cells, T-cell group was injected with the same total number of T cells as the CAR T-cell group, and medium control group was injected with cell preservation solution. (F-G) Bioluminescence image analysis. ∗P < .05; ∗∗∗P < .001 (n = 4).

In vitro function verification of S103 BCMA CAR T cells. (A) Schematic rep...

Open Access
in Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma > Blood Advances
Published: 2025
Figure 1. In vitro function verification of S103 BCMA CAR T cells. (A) Schematic representation of S103 CAR structure. (B) CAR transduction efficiency of S103 CAR T cells. (C) Cell viability of S103 CAR T cells at different culture stages, the x-axis represents the culture days, the red line rep... More about this image found in In vitro function verification of S103 BCMA CAR T cells. (A) Schematic rep...
Images
OS and PFS of the 27 patients with R/R MM treated with S103 BCMA CART.

OS and PFS of the 27 patients with R/R MM treated with S103 BCMA CART.

Open Access
in Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma > Blood Advances
Published: 2025
Figure 2. OS and PFS of the 27 patients with R/R MM treated with S103 BCMA CART. More about this image found in OS and PFS of the 27 patients with R/R MM treated with S103 BCMA CART.
Images
The long-term follow-up data for the 27 patients with R/R MM treated with S103 BCMA CAR T-cell therapy.

The long-term follow-up data for the 27 patients with R/R MM treated with S...

Open Access
in Efficacy and safety of BCMA nanobody CAR T-cell therapy in relapsed or refractory plasma cell myeloma > Blood Advances
Published: 2025
Figure 3. The long-term follow-up data for the 27 patients with R/R MM treated with S103 BCMA CAR T-cell therapy. More about this image found in The long-term follow-up data for the 27 patients with R/R MM treated with S...